Compare · CVRX vs DXCM
CVRX vs DXCM
Side-by-side comparison of CVRx Inc. (CVRX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 374.7x CVRX ($89.8M).
- CVRX has been more active in the news (13 items in the past 4 weeks vs 9 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 16 for CVRX).
- Company
- CVRx Inc.
- DexCom Inc.
- Price
- $3.38+7.12%
- $89.16-2.09%
- Market cap
- $89.8M
- $33.65B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 13
- 9
- Recent ratings
- 16
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CVRX
- CVRx Responds to Letter from Pointillist Family Office
- Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
- CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
- CHIEF OPERATING OFFICER Binkowski Brent bought $76,432 worth of shares (26,223 units at $2.91), increasing direct ownership by 87% to 56,514 units (SEC Form 4)
- CHIEF OPERATING OFFICER Binkowski Brent sold $3,338 worth of shares (1,309 units at $2.55), decreasing direct ownership by 4% to 30,291 units (SEC Form 4) (tax liability)
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Announces Sales Leadership Transition
- CVRx, Inc. downgraded by Craig Hallum with a new price target
- CVRx, Inc. downgraded by Lake Street with a new price target
- CVRx, Inc. downgraded by Piper Sandler with a new price target
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.